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Background: Epigenetic modifications play important roles in the regulation of gene expression determining
cellular phenotype as well as various pathologies such as cancer. Although the loss of keratin 13 (KRT13) is
reportedly linked to malignant transformation of oral epithelial cells, the molecular mechanisms through which
KRT13 is repressed in oral squamous cell carcinoma (OSCC) remain unclear. The aim of this study is to identify
the epigenetic alterations of the KRT13 gene in OSCCs.
Methods: We investigated KRT13 expression levels and chromatin modifications of the KRT13 promoter in the three
OSCC cell lines (HSC4, HSC3, and SAS). The expression levels of KRT13 protein and mRNA were analyzed by western
blotting and quantitative reverse-transcription polymerase chain reaction, respectively, and the localization of KRT13
protein was detected by immunofluorescence. DNA methylation and histone modifications in the KRT13 promoter were
determined by bisulfite sequencing and chromatin immunoprecipitation (ChIP), respectively. For the pharmacological
depletion of Polycomb repressive complex 2 (PRC2), cells were treated with 3-deazaneplanocin A (DZNep).
Results: KRT13 expression was transcriptionally silenced in the HSC3 and SAS cells and post-transcriptionally repressed in
the HSC4 cells, while the KRT13 promoter was hypermethylated in all of the three OSCC cell lines. ChIP analysis revealed
that PRC2-mediated trimethylation of Lys 27 on histone H3 (H3K27me3) was increased in the KRT13 promoter in the
HSC3 and SAS cells. Finally, we demonstrated that the treatment of SAS cells with DZNep reactivated the transcription
of KRT13 gene.
Conclusions: Our data provide mechanistic insights into the epigenetic silencing of KRT13 genes in OSCC cells
and might be useful for the development of diagnostic markers and novel therapeutic approaches against OSCCs.
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Gene silencingBackground
Epigenetic mechanisms play important roles in the
regulation of gene expression and phenotypic plasticity.
The addition of a methyl group to the cytosine of a CpG
dinucleotide (i.e., DNA methylation) in the promoter
region of genes commonly mediates gene repression
and acts as a silencing mechanism [1]. Post-translational
modifications of histone tails are important regulatory
markers for generating transcriptionally active and in-
active chromatin. For instance, the trimethylation of Lys
4 on histone H3 (H3K4me3) is associated with gene
activation, while the methylation of H3K27 (H3K27me3)* Correspondence: hatta@college.fdcnet.ac.jp
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unless otherwise stated.and H3K9 (H3K9me2 and H3K9me3) is often connected
to gene repression [2,3]. These epigenetic modifications
dynamically regulate the chromatin architecture of
promoter regions leading to the establishment of gene
expression patterns. Polycomb repressive complex 2 (PRC2)
comprises four core components (Ezh2, Suz12, Eed, and
RbAp46/48) and several other proteins [4]. Ezh2 contains
histone methyltransfease activity and plays an important
role in the methylation of H3K27 mediated by PRC2.
Dysregulation of PRC2 has been linked to several human
cancers including lymphoma, squamous cell carcinoma, and
breast and prostate cancer [5-9].
Oral squamous cell carcinoma (OSCC) is the most
common neoplasm of the oral cavity and has poor clin-
ical outcomes associated with recurrence and metastasistral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Naganuma et al. BMC Cancer 2014, 14:988 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/988[10]. The Keratin 13 (KRT13) gene encodes a type I
acidic keratin which is expressed in the differentiated
cells of non-cornified stratified squamous epithelia [11-13].
Notably, the disappearance of KRT13 is often seen in
OSCC lesions, while KRT13 is expressed in normal non-
cornified oral mucosa [14-19]. In addition, KRT13-negative
OSCC is associated with a high potential for local recur-
rence [20]. Although the loss of KRT13 is correlated with
the cellular transformation of oral epithelial cells, the
epigenetic mechanisms by which KRT13 is repressed in
OSCCs remain unclear.
In this study, we examined the epigenetic alterations
in OSCC cells by focusing on the silencing mechanisms
of the KRT13 gene and showed elevated KRT13 pro-
moter DNA methylation and repressive histone modifi-
cations in OSCC cell lines. Furthermore, we found a
PRC2 inhibitor effective for restoring KRT13 transcrip-
tion. Our findings provide molecular insights into the
epigenetic silencing of the KRT13 gene in OSCC cells as
well as important implications for the development of
diagnostic markers and novel therapeutic approaches.
Methods
Ethics statement
All experiments in this manuscript have been approved
by the Fukuoka Dental College Institutional Biosafety
Committee.
Cells and drug treatment
HSC3 and HSC4 cells were cultured as described previ-
ously [21]. Immortalized human keratinocyte HaCaT
cells and OSCC-derived SAS cells were maintained in
Dulbecco’s Modified Eagle’s Medium supplemented with
10% fetal bovine serum, 50 units/ml penicillin, and
50 μg/ml streptomycin and maintained at 37°C with 5%
CO2. The potent PRC2 inhibitor 3-deazaneplanocin A
(DZNep) was purchased from Sigma-Aldrich (St. Louis,
MO). Cells were seeded the day before the drug treatment,
and DZNep (10 μM) was added to the culture medium for
24 h or 72 h.
DNA methylation analysis
Genomic DNA was extracted from cells using the
NucleoSpin Tissue kit (Macherey-Nagel, Düren, Germany)
and subjected to bisulfite modification using the Methyl-
Easy Xceed kit (Human Genetic Signatures, Randwick,
Australia) according to the manufacturer’s instructions.
The primers used for amplification of the KRT13 promoter
after bisulfite modification were 5′-TGGAGTAGATGAA
GTGCTAAGAAGG-3′ and 5′-AACAAAAAGAATGATT
CAGAGGGG-3′. Polymerase chain reaction (PCR) was
performed with EX-taq DNA polymerase (Takara Bio Inc.,
Shiga, Japan), followed by TA cloning into a pMD20-T
vector (Takara Bio Inc.) and sequencing of individual clones.Quantitative RT-PCR
Total RNA was extracted from cells using the Nucleo-
Spin RNA kit (Macherey-Nagel) and reverse transcrip-
tion was performed using a PrimeScript RT reagent kit
(Takara Bio Inc.) according to the manufacturer’s instruc-
tions. Quantitative reverse-transcription PCR (RT-PCR)
was performed on an ABI 7500 real-time PCR system
(Applied Biosystems, Carlsbad, CA) using SYBR Premix Ex
Taq II (Takara Bio Inc.). The primers used for KRT13 were
5′-GACCGCCACCATTGAAAACAA-3′ and 5′-TCCAG
GTCATTAGACAGAG-3′. GAPDH was used as a refer-
ence gene for normalization. The primers used for GAPDH
were 5′-GGAGCGAGATCCCTCCAAAAT-3′ and 5′-GG
CTGTTGTCATACTTCTCATGG-3′. PCR conditions were
as follows: 95°C for 30 sec, followed by 45 cycles of 95°C
for 10 sec and 60°C for 1 min. The relative standard
curve method was used to quantify relative mRNA levels
of KRT13 and GAPDH.
Western blotting
Cells were scraped and resuspended in RIPA buffer
(25 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 1%
Noidet P-40, 5 mM EDTA, 1% sodium deoxycholate).
Total protein extracts (5–10 μg) were resolved by
electrophoresis on 4–20% polyacrylamide-SDS gels and
transferred onto polyvinylidene fluoride membranes. The
membranes were blocked with 4% (w/v) ECL Prime block-
ing agent (GE Healthcare Life Sciences, Backinghamshire,
UK) in 0.1% Tween-TBS and probed with primary anti-
bodies, followed by horseradish peroxidase-conjugated
secondary antibodies. The specific antigen-antibody inter-
actions were detected on a LAS-2000 imaging system (Fuji
Film, Tokyo, Japan) using an ECL Prime Western Blotting
Detection Reagent (GE Healthcare Life Sciences). Quanti-
fication of band intensity was performed using ImageJ
1.47v (National Institute of Health, Bethesda, MD).
Relative expression levels were normalized to β-actin or
histone H3. The following primary antibodies were used
in this study: anti-keratin 13 (EPR3671; Abcam, Cambridge,
UK; dilution, 1:1000), anti-Ezh2 (#5246; Cell Signaling
Technology, Danvers, MA; dilution, 1:1000), anti-Suz12
(#3737; Cell Signaling Technology; dilution, 1:1000), anti-
histone H3 (#4499; Cell Signaling Technology; dilution,
1:1000), anti-trimethyl histone H3 (Lys27) (MAB323B;
MAB Institute Inc., Sapporo, Japan; dilution, 1:1000), and
anti-β-actin (sc-47778; Santa Cruz Biotechnology, Dallas,
TX; dilution, 1:2000).
Immunofluorescence
Cells were plated on Nunc Lab-Tek chamber slides
(177429; Thermo Scientific, Waltham, MA), incubated for
24 h, fixed with 4% paraformaldehyde in PBS for 20 min
at 21–25°C, permeabilized with 0.1% Triton X-100
for 30 min, and washed three times with PBS. Cells
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Tween 20 in PBS and probed with anti-keratin 13
(EPR3671; Abcam, dilution; 1:100), followed by anti-
rabbit immunoglobulin-G (IgG) antibody conjugated with
Alexa Fluor 488 (A-11034; Life Technologies, Carlsbad,
CA; dilution, 1:800). Nuclei were counterstained with
DAPI (P36935; Life Technologies). Fluorescence imaging
was performed and images were captured using a Biorevo
microscope (BZ-9000; Keyence, Osaka, Japan).
Chromatin immunoprecipitation
Cells were fixed in culture medium containing 1%
formaldehyde for 10 min at 21–25°C and incubated in
NP-40 buffer (10 mM Tris–HCl pH 8.0, 10 mM NaCl,
0.5% NP-40) for 5 min at 21–25°C. Cell were harvested
and resuspended in SDS lysis buffer (50 mM Tris–HCl
pH 8.0, 1% SDS, 10 mM EDTA), followed by 5-fold dilu-
tion in chromatin immunoprecipitation (ChIP) dilution
buffer (50 mM Tris–HCl pH 8.0, 167 mM NaCl, 1.1%
Triton X-100, 0.11% sodium deoxycholate). Chromatin
was sonicated using a Bioruptor (Cosmo Bio Co., Tokyo,
Japan) at medium power ten times for 20 sec. Ten
micrograms of soluble sheared chromatin was incubated
overnight at 4°C with protein G magnetic beads (#9006;
Cell Signaling Technology) bound to 2 μg anti-histone
H3 (#4620; Cell Signaling Technology), anti-trimethyl
histone H3 (Lys4) (#9751; Cell Signaling Technology),
anti-trimethyl histone H3 (Lys27) (#9733; Cell Signaling
Technology), or control IgG (Cell Signaling Technology
#2729), followed by sequential washing with low salt
RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 1% Triton X-100, 0.1% sodiumFigure 1 Loss of KRT13 protein in oral squamous cell carcinoma (OSC
cells were examined by western blotting. Representative images are shown
intensity of the HaCaT cells and normalized to that of β-actin. The means ±
performed by a one-way analysis of variance followed by Dunnett’s post h
immunofluorescence staining, and nuclei were visualized with DAPI stainindeoxycholate), high salt RIPA buffer (50 mM Tris–HCl
pH 8.0, 500 mM NaCl, 1 mM EDTA, 0.1% SDS, 1%
Triton X-100, 0.1% sodium deoxycholate), wash buffer
(50 mM Hepes-KOH pH 7.5, 500 mM LiCl, 1 mM
EDTA, 1% NP-40, 0.7% sodium deoxycholate), and TE
buffer. Immune complexes were then eluted by incuba-
tion for 20 min at 65°C with ChIP direct elution buffer
(50 mM Tris–HCl, pH 8.0, 10 mM EDTA, 1% SDS), and
the cross-linking was reversed by incubating overnight
at 65°C. DNA was purified using the GenElute PCR
Clean-up kit (Sigma-Aldrich) and subjected to quantita-
tive PCR on an ABI 7500 real-time PCR system (Applied




All values are presented as the means ± SEM for each
group. Statistical analysis was performed using Student’s
t-test to compare the means of two groups or by a one-
way analysis of variance followed by Dunnett’s post hoc
test for more than three groups. p < 0.05 was considered
significant.
Results
KRT13 repression by multiple mechanisms in OSCC cells
First, we examined KRT13 expression levels in the dif-
ferentiated OSCC cell line (HSC4), in the poorly differ-
entiated OSCC cell lines (HSC3 and SAS), and in the
immortalized human keratinocyte HaCaT cell line [22-24].
Western blotting showed that KRT13 protein levels were
significantly decreased in the HSC4 and HSC3 cellsC) cells. (A) KRT13 protein levels in three OSCC cell lines and HaCaT
. Fold change in KRT13 protein was calculated relative to band
SEM for each group (n = 4–5) are shown. Statistical analysis was
oc test. **p < 0.01. (B) Expression of KRT13 (green) was analyzed by
g (blue).
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SAS cells (Figure 1A). Immunofluorescence microscopy
revealed high cytoplasmic expression of KRT13 protein
in the HaCaT cells, but not in the OSCC cell lines
(Figure 1B and Additional file 1: Figure S1). To investigate
whether the reduction in KRT13 protein levels was due to
the reduced expression of KRT13 mRNA, we performed
quantitative RT-PCR analysis. As shown in Figure 2,
KRT13 mRNA levels were significantly decreased in the
HSC3 and SAS cells, but not in the HSC4 cells, compared
with HaCaT cells. These results suggest that KRT13 ex-
pression is likely to be repressed by translational inhibition
or protein degradation in the HSC4 cells and transcrip-
tionally silenced in the HSC3 and SAS cells.
KRT13 promoter methylated in OSCC cells
Since it has been reported that the methylation status of
the promoter region is generally linked to gene repres-
sion [1], we examined the DNA methylation status of
the KRT13 promoter in the OSCC cells. The CpG sites
within the proximal promoter region (−470 to −190) wereFigure 2 Silencing of the KRT13 gene in poorly differentiated
OSCC cells. KRT13 mRNA levels in three OSCC cell lines and HaCaT
cells were analyzed by quantitative reverse-transcription polymerase
chain reaction (RT-PCR). Fold change in KRT13 mRNA was normalized
to GAPDH and calculated relative to that of the HaCaT cells. The
means ± SEM for each group (n = 3) are shown. Statistical analysis was
performed by a one-way analysis of variance followed by Dunnett’s
post hoc test. **p < 0.01, N.S. (not significant).analyzed by bisulfite sequencing (Figure 3A). As shown in
Figure 3B, the KRT13 promoter was partially methylated
(<50%) in the HaCaT cells and highly methylated (≥90%) in
the three OSCC cell lines (HSC4, HSC3, and SAS). These
data show that the KRT13 promoter was aberrantly hyper-
methylated in all of the examined OSCC cell lines.
Alterations of histone H3 methylation patterns in the
KRT13 promoter in OSCC cells
DNA methylation of the KRT13 promoter did not
correlate with KRT13 gene repression. Thus, it is likely
that alterations of histone modifications are responsible
for KRT13 gene repression in OSCC cells. It has been
reported that H3K4me3 is associated with active
transcription, while H3K27me3 is generally linked to
gene repression [2,3]. We therefore examined histone H3
methylation patterns at the KRT13 promoter in the
HaCaT cells and the three OSCC cell lines. ChIP analysis
demonstrated that high levels of H3K4me3 but low levelsFigure 3 DNA methylation status of the KRT13 promoter in
OSCC cells. (A) Schematic of the KRT13 gene promoter region. The
tick represents individual CpG sites and the arrow represents the
transcription start site. The bar indicates the region (−470 to −190)
subjected to DNA methylation analysis. (B) CpG methylation status
of the KRT13 promoter in the three OSCC cell lines and HaCaT cells.
Open and closed circles represent methylated and unmethylated
CpG sites, respectively. The absence of circles indicates missing data.
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which KRT13 mRNA was highly expressed. On the other
hand, HSC3 and SAS cells showed a histone code switch
to high H3K27me3 but low K4me3 (Figure 4A). Addition-
ally, we observed high levels of H3K9me2 and K9me3, and
low occupancy of RNA polymerase II (RNAP II) at the
KRT13 promoter in the SAS cells compared with the
HaCaT cells (Additional file 2: Figure S2A and B). Since
PRC2 is known to play an important role in gene repres-
sion through the demethylation of H3K4 and the trimethy-
lation of H3K27 and is linked to human cancer [5-9], we
examined the expression levels of PRC2 component pro-
teins (Ezh2 and Suz12) by western blotting. As shown in
Figure 4B, we found no significant differences in the levels
of Ezh2 and Suz12 proteins among the four cell lines.
These data suggest that the histone H3 methylation pat-
terns in the KRT13 promoter of the poorly differentiated
OSCC cell lines (HSC3 and SAS) are distinct from those of
the HaCaT and HSC4 cells and that the aberrant targeting
of PRC2 to the KRT13 promoter may cause this site-
specific alteration.
Reactivation of KRT13 transcription by the PRC2 inhibitor
DZNep in OSCC cells
To determine whether PRC2-mediated transcriptional
repression is responsible for KRT13 gene silencing, weFigure 4 Alterations of histone modifications in the KRT13 promoter
gene. The arrow represents the transcription start site, and arrowheads ind
patterns of histone H3 (H3K4me3 and H3K27me3) in the KRT13 promoter i
chromatin immunoprecipitation (ChIP) assay. Fold enrichment of histone H
relative to that of HaCaT cells. The value of H3K4me3 in the HaCaT cells wa
Statistical analysis was performed using Student’s t-test. *p < 0.05, **p < 0.0
the three OSCC cell lines and HaCaT cells by western blotting. Representat
normalized to β-actin and calculated relative to band intensity of the HaCa
analysis was performed by a one-way analysis of variance followed by Dunexamined the effects of the potent PCR2 inhibitor DZNep
on KRT13 mRNA expression in the SAS cells. As shown
by western blotting (Figure 5A), treatment of the SAS cells
with 10 μM DZNep for 24 h decreased the Ezh2 and
Suz12 protein levels and H3K27 trimethylation levels, and
KRT13 mRNA expression was markedly increased by
almost 30-fold after DZNep treatment (Figure 5B). In
addition, the H3K27me3 levels in the KRT13 promoter
were reduced in the SAS cells treated with DZNep
(Figure 5C). We then investigated the reversibility of
DZNep-induced KRT13 transcription in SAS cells, which
had been treated with DZNep for 24 h. KRT13 mRNA
levels were increased after additional exposure to DZNep
for 48 h, whereas the mRNA levels were reversed for 48 h
after withdrawing DZNep (Figure 6A). As shown in
Figure 6B, the Ezh2 and Suz12 protein levels were de-
creased by DZNep treatment, and increased more than
normal levels after drug removal. Taken together, our data
suggest that DZNep induces the down-regulation of Ezh2
proteins and reactivates the transcription of KRT13 gene
in SAS cells and that the effects of DZNep treatment on
SAS cells are not heritable changes.
Discussion
This study provides molecular insights into the epi-
genetic silencing of the KRT13 gene in OSCC cells.in OSCC cells. (A) Schematic of the promoter region of the KRT13
icate the primer set used for quantitative PCR. The methylation
n the three OSCC cell lines and HaCaT cells were examined by
3 modifications was normalized to total histone H3 and calculated
s set to 1. The means ± SEM for each group (n = 3–5) are shown.
1. (B) The levels of PRC2 proteins (Ezh2 and Suz12) were analyzed in
ive images are shown. Fold change in Ezh2 and Suz12 proteins were
T cells. The means ± SEM for each group (n = 3) are shown. Statistical
nett’s post hoc test. N.S. (not significant).
Figure 5 Effects of 3-deazaneplanocin A (DZNep) on KRT13 expression in OSCC cells. (A) SAS cells were treated with 10 μM DZNep for
24 h, and the levels of the PRC2 proteins (Ezh2 and Suz12) and H3K27me3 were examined by western blotting. Fold change in PRC2 proteins
and H3K27me3 were normalized to β-actin and total histone H3, respectively, and calculated relative to band intensity of the control condition
samples. The means ± SEM for each group (n = 3) are shown. Statistical analysis was performed using Student’s t-test. **p < 0.01. (B) KRT13 mRNA
levels were analyzed by quantitative RT-PCR. Fold change in KRT13 mRNA was normalized to GAPDH and calculated relative to that of the cells
under the control condition. The means ± SEM for each group (n = 3) are shown. Statistical analysis was performed using Student’s t-test. **p < 0.01.
(C) H3K27me3 levels in the KRT13 promoter were analyzed by ChIP assay. Fold enrichment of histone H3K27me3 was normalized to that of total
histone H3 and calculated relative to that of the cells under the control condition. The means ± SEM for each group (n = 3–5) are shown. Statistical
analysis was performed using Student’s t-test. *p < 0.05.
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play a critical role in transcriptional silencing [1], and it
has recently been reported that DNA methylation can dir-
ectly silence genes with non-CpG island promoters [25].
We therefore investigated the DNA methylation status of
the KRT13 promoter. According to the defining criteria of
CpG islands [26], the KRT13 promoter is classified as a
non-CpG promoter. Bisulfite sequencing revealed that the
KRT13 promoter was hypermethylated in all of the trans-
formed OSCC cells tested compared with immortalized
keratinocytes (Figure 3). Interestingly, Marsit et al. [27]
reported that the KRT13 gene was identified as one of the
methylated genes associated with aggressive bladder
cancer. It is possible that the aberrant DNA methylation
patterns of the KRT13 promoter are a hallmark for certain
types of cancer.
We evaluated KRT13 expression levels by western blot-
ting, immunocytochemistry, and quantitative RT-PCR.
KRT13 protein levels were significantly reduced in all threeOSCC cell lines (Figure 1), while KRT13 transcription
levels were decreased in the poorly differentiated OSCC
cell lines (HSC3 and SAS), but not in the differentiated
OSCC cell line HSC4 (Figure 2). This finding is consist-
ent with a previous immunohistochemistry study using
paraffin sections of oral carcinoma in situ [16]. Thus, it
is likely that OSCC cells repress KRT13 through mul-
tiple mechanisms. Our bisulfite sequencing data suggest
that DNA methylation in the KRT13 promoter does
not directly mediate transcriptional silencing, and that
additional events, such as histone modifications, are re-
quired for KRT13 gene silencing in the poorly differen-
tiated OSCC cells.
Epigenetic changes of histone modifications (low
H3K4me3 and high H3K27me3) in the KRT13 promoter
were identified in the HSC3 and SAS cells (Figure 4). We
focused on PRC2-mediated H3K27me3, since it has been
reported that H3K27me3 and the PRC2 component Ezh2
are involved in squamous cell differentiation [28], and that
Figure 6 Reversibility of DZNep-induced KRT13 expression in OSCC cells. (A) Schematic of DZNep treatment time. The inverted triangle
denotes the starting point. White and black boxes represent incubation without and with 10 μM DZNep, respectively. SAS cells were incubated
without DZNep for 72 h (control), with DZNep for 72 h (DZNep (+)), or with DZNep for 24 h followed by the removal of DZNep (DZNep (+/−)).
KRT13 mRNA levels were analyzed by quantitative RT-PCR. Fold change in KRT13 mRNA was normalized to GAPDH and calculated relative to that
of the cells under the control condition. The means ± SEM for each group (n = 3) are shown. Statistical analysis was performed by a one-way
analysis of variance followed by Dunnett’s post hoc test. **p < 0.01, N.S. (not significant). (B) Ezh2 and Suz12 protein levels were examined by
western blotting. Representative images are shown. Fold change in Ezh2 and Suz12 proteins was normalized to β-actin and calculated relative to
band intensity of the control condition samples. The means ± SEM for each group (n = 4) are shown. Statistical analysis was performed by a
one-way analysis of variance followed by Dunnett’s post hoc test. **p < 0.01.
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http://www.biomedcentral.com/1471-2407/14/988deregulation of PRC2 proteins is closely related to several
human tumors [5-9]. To examine the recruitment of
PRC2 proteins to the KRT13 promoter in SAS cells, we
pharmacologically depleted PRC2 proteins. DZNep was
previously reported to deplete the cellular levels of
PRC2 proteins and inhibit H3K27 trimethylation [29].
DZNep treatment reduced PRC2 proteins and H3K27me3
levels and reactivated the KRT13 transcription in the
SAS cells (Figures 5 and 6). KRT13 is also expressed in
the differentiated epithelial cells of the suprabasal layer
[11-13], while Ezh2 is expressed in the basal layer of
stratified squamous epithelia [28]. In addition to the
loss of KRT13, the overexpression of Ezh2 has been re-
ported to correlate with malignant potential and poor
prognosis in human OSCCs [6]. Our data suggest that
KRT13 is one of the PRC2-repressed target genes in OSCC
cells and that the reciprocal expression of KRT13
and PRC2 serves as a useful biomarker for phenotypic
characterization of OSCC cells.Conclusions
In summary, our study highlights the epigenetic mecha-
nisms of KRT13 silencing in OSCC cells. We identified
epigenetic alterations in the KRT13 promoter in OSCC
cells and showed that the pharmacological inhibition of
PRC2 restored KRT13 expression. To our knowledge,
this is the first report on PRC2-mediated epigenetic
silencing of KRT13. Our findings may be useful for the
development of diagnostic markers and novel therapeutic
approaches against OSCCs.
Additional files
Additional file 1: Figure S1. Cytoplasmic expression of KRT13 protein
in the HaCaT cells. HaCaT cells were fixed and probed with anti-keratin
13 (EPR3671; Abcam; dilution, 1:100) or normal rabbit IgG (#2729; Cell
Signaling Technology; dilution, 1:100), followed by anti-rabbit IgG antibody
conjugated with Alexa Fluor 488. Expression of KRT13 protein (green) was
analyzed using a confocal microscope (LSM710; Carl Zeiss MicroImaging
GmbH, Jena, Germany), and nuclei were visualized with DAPI staining (blue).
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http://www.biomedcentral.com/1471-2407/14/988Additional file 2: Figure S2. Methylation of H3K9 and reduced RNAP II
occupancy at the KRT13 promoter in the SAS cells. (A) Methylation of
H3K9 were analyzed by ChIP assay using anti-dimethyl histone H3 (Lys9)
(#4658; Cell Signaling Technology), anti-trimethyl histone H3 (Lys9)
(MA308B; MAB Institute Inc.). Fold enrichment of histone H3K9me2 and
K9me3 were normalized to total histone H3 and calculated relative to
that of the HaCaT cells. The means ± SEM for each group (n = 3) are
shown. Statistical analysis was performed using Student’s t-test. *p < 0.05,
**p < 0.01. (B) RNA polymerase II (RNAP II) occupancy at the KRT13
promoter was analyzed by ChIP assay using anti-RNAP II (clone 4H8;
Active Motif, Carlsbad, CA). Fold enrichment of RNAP II was normalized
to negative control IgG and calculated relative to that of the HaCaT
cells. The means ± SEM for each group (n = 3) are shown. Statistical analysis
was performed using Student’s t-test. *p < 0.05.Competing interests
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